Alan Baer, MD
Rheumatology · Baltimore, MDNPI 1730155607
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.1%), travel and lodging and grants — rather than concentrated in one kind of arrangement. E.r. Squibb & Sons, L.L.C. accounts for 68.3% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $18,146 and has fallen 79.7% since, to $3,689 in 2025.
Across 29 payments — averaging $1086.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$22K
- Novartis$4K
- Sanofi-aventis U.S. LLC$3K
- Argenx US, Inc.$3K
- Amgen$198
- Bausch & Lomb Americas Inc.$129
- plus $272 from 4 others
Across 6 payments — averaging $40,857 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$245K
- E.r. Squibb & Sons, L.L.C.$23
What the payments were for
- Consulting fees$14,82947%
- Grants$3,65712%
- Travel & lodging$12,21339%
- Food & beverage$7973%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 19 | $21,512 |
| Novartis | 1 | $3,657 |
| Sanofi-aventis U.S. LLC | 1 | $2,916 |
| Argenx US, Inc. | 1 | $2,813 |
| Amgen | 1 | $198 |
| Bausch & Lomb Americas Inc. | 1 | $129 |
| Johnson & Johnson | 1 | $100 |
| Mallinckrodt Hospital Products Inc. | 1 | $100 |
| Janssen Global Services, LLC | 2 | $53 |
| Boston Scientific | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,496 in reported general payments places this provider in the 85th percentile of 173 rheumatology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 21 | $168,604 |
| XeljanzTofacitinib Citrate | 15 | $112,362 |
| Humira PenAdalimumab | 13 | $103,785 |
| Hydroxychloroquine Sulfate | 135 | $8,552 |
| Cevimeline Hcl | 32 | $6,506 |
| Mycophenolate Mofetil | 19 | $2,206 |
| Pilocarpine Hcl | 44 | $2,084 |
| MethotrexateMethotrexate Sodium | 37 | $1,778 |
| Gabapentin | 33 | $1,221 |
| Prednisone | 63 | $716 |
| Allopurinol | 39 | $548 |
| Duloxetine Hcl | 12 | $543 |
| Colchicine | 14 | $405 |
| Fluconazole | 22 | $336 |
| LoperamideLoperamide Hcl | 12 | $230 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Baltimore
- Michelle PetriBaltimore$381K
- Marc HochbergBaltimore$124K
- Clifton BinghamBaltimore$117K
- Lisa ChristopherBaltimore$92K
- Philip SeoBaltimore$84K
- Laura HummersBaltimore$80K
- Rachel WallworkBaltimore$71K
- Thomas Grader BeckBaltimore$55K
- Andrea FavaBaltimore$38K
- Christopher MecoliBaltimore$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.